News
TENX
3.390
+2.11%
0.070
Weekly Report: what happened at TENX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at TENX last week (0708-0712)?
Weekly Report · 07/15 09:34
Weekly Report: what happened at TENX last week (0701-0705)?
Weekly Report · 07/08 09:35
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. Akso Health Group stock rose 11.68% and Sharps Technology stock rose 33.56% during the session.
Benzinga · 07/04 16:31
Weekly Report: what happened at TENX last week (0624-0628)?
Weekly Report · 07/01 09:35
Weekly Report: what happened at TENX last week (0617-0621)?
Weekly Report · 06/24 09:37
Weekly Report: what happened at TENX last week (0610-0614)?
Weekly Report · 06/17 09:34
Tenax Therapeutics Enhances Incentives and Adjusts Leadership Structure
TipRanks · 06/13 21:15
Weekly Report: what happened at TENX last week (0603-0607)?
Weekly Report · 06/10 09:35
Weekly Report: what happened at TENX last week (0527-0531)?
Weekly Report · 06/03 09:36
Weekly Report: what happened at TENX last week (0520-0524)?
Weekly Report · 05/27 09:37
Weekly Report: what happened at TENX last week (0513-0517)?
Weekly Report · 05/20 09:36
Tenax Therapeutics, Inc. Quarterly Report on Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/14 20:21
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024
Tenax Therapeutics reported earnings per share of -$ for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for -$ . Tenax Therapedutics is a biopharmaceutical company with a focus on cancer treatment.
Investorplace · 05/14 17:53
Tenax Therapeutics GAAP EPS of -$3.12
Seeking Alpha · 05/14 14:42
Tenax Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Tenax Therapeutics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of $ per share. The mean expectation of two analysts was for the company to report a loss of in the quarter. The average analyst rating on the company's shares is "buy"
Reuters · 05/14 14:25
Tenax Therapeutics Q1 EPS $(3.12) Misses $(2.40) Estimate
Benzinga · 05/14 12:25
Tenax Therapeutics: Q1 Earnings Snapshot
Tenax Therapeutics Inc. On Tuesday reported a loss of $ million in its first quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a lost of $ in the quarter. The company says it lost $.
Barchart · 05/14 07:10
Weekly Report: what happened at TENX last week (0506-0510)?
Weekly Report · 05/13 09:38
Weekly Report: what happened at TENX last week (0429-0503)?
Weekly Report · 05/06 09:40
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).